早期非小细胞肺癌组织中表皮生长因子受体Kras和BRAF基因突变及其临床意义  

The mutation of EGFR,Kras and Braf related to clinical significance in early Non-small Cell Lung Cancer

作　　者：肖旺[1,2] 王伟 李军 李学昌 尚立群 文锋 刘军强 宋伟安 岳彩迎 查鹏 

机构地区：[1]南方医科大学研究生学院,广州510515 [2]北京海军总医院胸外科,北京100048

出　　处：《中国肿瘤临床与康复》2015年第5期522-525,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨Kras基因、BRAF基因与表皮生长因子受体(EGFR)之间的关系,为进一步研究Ras-Raf-MEK-ERK通路导致EGFR-TKI耐药的具体机制奠定基础。方法获取74例经手术治疗,术后未行放化疗和(或)靶向药物治疗的非小细胞肺癌(NSCLC)患者的肿瘤组织标本,检测EGFR各位点,Kras及BRAF基因的突变,并做相关性分析。结果 EGFR exon 19、exon 21与Kras突变存在负相关,(相关系数r分别为-0.345和-0.309,P<0.01)。EGFR与BRAF,Kras与BRAF之间不存在相关性(P>0.01)。结论 EGFR突变与Kras突变呈负相关,与BRAF突变不存在相关性,Kras与Braf突变不相关,提示EGFR、Kras和Braf突变为相互独立的过程。Objective To explore the relationship between EGFR,KRAS and BRAF gene, and lay the foundation for the related mechanisms of Ras-Raf-MEK-ERK pathway in EGFR-TKI resistance, neth- otis Detect the mutation of EGFR,KRAS and BRAF gene in 74 NSCLC patients with operation treatment but not chemotherapy or targeted therapy, and the correlation was analyzed. Results EGFR exon 19,exon 21 and Kras gene mutations has negative correlation with each other （r =-0. 345,0. 309,P 〈 0.01 ）, but EGFR and Braf are uncorrelated,neither of Kras and Braf（P 〉 0. 01 ）. Conclusions EGFR gene mutations is negative related to Kras, but EGFR and Braf, Kras and Braf have no correlation to each other, which in- dicate that the mutation of EGFR , Kras and Braf gene are mutually independent to each other.

关 键 词：表皮生长因子受体 KRAS基因 BRAF基因 癌 非小细胞肺 

分 类 号：R734.2[医药卫生—肿瘤]